Anat Cohen-Dayag

This inventor holds 7 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Compugen Ltd. Corporation. Active years: 2009-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anat Cohen-Dayag. Retrieved from https://idiyas.com/inventor/anat-cohen-dayag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 13)

% Patents Active = 28.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 11.5

ph-index = 4

Forward Citations = 30(Granted Patents)

Company Filing History:

7 out of 62

Compugen Ltd. Corporation

patents

Years Active: 2009-2018

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10098934 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2018-10-16),

2. 9555087 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2017-01-31),

3. 9375466 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2016-06-28),

4. 9107862 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2015-08-18),

5. 8415455 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2013-04-09),

6. 7741433 - Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof (2010-06-22),

7. 7488813 - Diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof (2009-02-10),

Title: The Innovative Contributions of Anat Cohen-Dayag

Introduction

Anat Cohen-Dayag is a prominent inventor based in Rehovot, Israel. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of seven patents to her name, her work focuses on novel drug targets for immune and non-immune based therapeutics.

Latest Patents

One of her latest patents involves polypeptides and polynucleotides, which serve as drug targets for producing drugs and biologics. This invention relates to a novel target for the production of immune and non-immune based therapeutics and for disease diagnosis. More specifically, it provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32, or FXYD3 antigens. These antigens are predicted co-stimulatory family members that are differentially expressed in various cancers, including lung cancer, ovarian cancer, and colon cancer. The invention also outlines diagnostic and therapeutic usages, including the modulation of B7 costimulation and related therapies for treating autoimmunity. Furthermore, it highlights the discovery of extracellular domains of these antigens and their variants, which are suitable targets for immunotherapy, cancer therapy, and drug development.

Career Highlights

Anat Cohen-Dayag is currently associated with Compugen Ltd. Corporation, where she continues to advance her research and innovations. Her work has positioned her as a key figure in the biotechnology sector, contributing to the development of cutting-edge therapies.

Collaborations

Anat collaborates with notable colleagues, including Shira Walach and Amir Toporik, who contribute to her research endeavors and innovations.

Conclusion

Anat Cohen-Dayag's contributions to biotechnology and her innovative patents underscore her role as a leading inventor in the field. Her work not only advances scientific knowledge but also holds the potential for significant therapeutic applications.

Profile summary based on public USPTO records.